Department of Biomedical Engineering, Lund University, PO Box 118, 221 00, Lund, Sweden.
Department of Orthopaedics, Clinical Sciences, Lund University and Skåne University Hospital, Lund, Sweden.
Osteoporos Int. 2017 Feb;28(2):697-707. doi: 10.1007/s00198-016-3771-8. Epub 2016 Nov 7.
Osteoporotic fractures may pose a challenge for skeletal regeneration. This study investigates if pharmaceutical interventions such as bone morphogenetic protein 7 (BMP-7) alone or in combination with Zoledronate have equivalent efficacy in osteoporotic bone? Our findings suggest they do and that an osteoporotic bone environment may increase sensitivity to BMP-7.
Osteoporosis is thought to contribute to delayed or impaired bone healing. Bone morphogenetic protein 7 (BMP-7) alone or synergistically combined with zoledronate (ZA) has proven effective in augmenting the regenerative response in healthy young male rats. Yet their comparative efficacy in an osteoporotic bone environment is unknown. Our study aimed to answer the following questions using the ovariectomized (OVX) rat model of osteoporosis: Do osteoporotic fractures pose a greater challenge for skeletal regeneration? Are interventions with BMP-7-alone or combined with ZA of equivalent efficacy in osteoporotic bone?
Sham operations (n = 33) or ovariectomies (n = 34) were performed in 12-week-old female Sprague-Dawley rats. Mid-diaphyseal open femoral osteotomies were created at 24 weeks of age and the rats allocated to either (i) untreated, (ii) BMP-7-only or (iii) BMP-7 + ZA treatment groups. At 6 weeks post-osteotomy, fracture healing was evaluated by radiography, μCT and 3-point bending mechanical tests.
Cumulatively, radiological, micro-structural and mechanical measures were equivalent in both healthy and osteoporotic environments. A reduced response to BMP-7-alone was observed in healthy rats that may be age/gender- or protocol/fracture-model dependent. Conversely, the BMP-7-only treated OVX group attained 100 % union in addition to significantly increased measures of mineralized bone volume, total callus volume, peak force and absorbed energy relative to untreated OVX fractures.
Our findings refute the hypothesis that osteoporotic fractures constitute a greater recalcitrant challenge for skeletal regeneration. Furthermore, our results suggest that an oestrogen-deficient environment may in fact cause an increased sensitivity to BMP-7.
骨质疏松症被认为会导致骨愈合延迟或受损。单独使用骨形态发生蛋白 7(BMP-7)或与唑来膦酸(ZA)联合使用已被证明可有效增强健康年轻雄性大鼠的再生反应。然而,它们在骨质疏松骨环境中的比较疗效尚不清楚。我们的研究旨在使用去卵巢(OVX)骨质疏松大鼠模型回答以下问题:骨质疏松性骨折是否对骨骼再生构成更大挑战?在骨质疏松骨中,BMP-7 单独或与 ZA 联合干预的疗效是否相当?
12 周龄雌性 Sprague-Dawley 大鼠行假手术(n=33)或卵巢切除术(n=34)。24 周龄时,在股骨干中段行开放性髓内截骨术,将大鼠分配至未治疗组、BMP-7 单药组或 BMP-7+ZA 治疗组。截骨术后 6 周,通过放射学、μCT 和三点弯曲力学试验评估骨折愈合情况。
在健康和骨质疏松环境中,累积的影像学、微观结构和力学测量结果均相当。在健康大鼠中,单独使用 BMP-7 的反应降低,这可能与年龄/性别或方案/骨折模型有关。相反,BMP-7 单药治疗的 OVX 组除了未治疗的 OVX 骨折外,还达到了 100%的愈合,并且骨矿物质体积、总骨痂体积、峰值力和吸收能量的测量值显著增加。
我们的研究结果反驳了骨质疏松性骨折对骨骼再生构成更大挑战的假设。此外,我们的结果表明,雌激素缺乏环境实际上可能导致对 BMP-7 的敏感性增加。